A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Public ClinicalTrials.gov record NCT01286467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS
Study identification
- NCT ID
- NCT01286467
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- PF-04449913 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2011
- Primary completion
- May 9, 2012
- Completion
- Dec 27, 2012
- Last update posted
- Mar 5, 2024
2011 – 2012
United States locations
- U.S. sites
- 9
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Keck Hospital of University of Southern California | Los Angeles | California | 90033 | — |
| Los Angeles County-University of Southern California Medical Center | Los Angeles | California | 90033 | — |
| University of Southern California/Norris Comprehensive Cancer Center/Investigational Drug Service | Los Angeles | California | 90033 | — |
| University of Southern California/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Brigham and Women's Hospital (BWH) | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute (DFCI) | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01286467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01286467 live on ClinicalTrials.gov.